ICUI ICU Medical, Inc.
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About ICU Medical (NASDAQ: ICUI)
›
ICU Medical (NASDAQ: ICUI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 13,000 employees.
The shares were at 175.76 USD on 19 November 2026, up 35.5% over 52 weeks. Its 52-week range is 113.37 USD to 192.85 USD: the price is 8.9% below the high and 55.0% above the low.
At a market capitalisation of 4.40B USD, it trades at 73.5 times trailing earnings and 18.2 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 49.2, a premium of 49% for ICUI.
ICU Medical reports return on equity of 0.0%, an operating margin of 6.7% and revenue up 4.4% year over year.
Its debt exceeds its cash by 899.31M USD, a debt-to-equity ratio of 0.63. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 8 analysts cover the stock, with an average rating of Buy; their mean price target of 194.25 USD is 10.5% above the current price. The next earnings report is expected on 18 February 2027.